Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Breast Neoplasms 2Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Diseases, Male 1Castrate-resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

tildrakizumab 1sabizabulin 1pembrolizumab 1enzalutamide 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Castration Resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡